Acurx Q2 2026 earnings: per-share loss narrows as share count rises

Acurx Pharmaceuticals (NASDAQ: ACXP) reported a Q2 2026 net loss of $2.254 million, or $0.53 per basic and diluted share, versus a $2.246 million loss, or $1.89 per share, in Q2 2025; the release did not report quarterly revenue. The absolute loss was essentially unchanged because higher R&D spending for the recurrent C. difficile infection program was largely offset by lower G&A expense. Cash ended June 30 at $10.656 million following equity financing during the quarter.

Core earnings data

Total operating expenses increased by approximately 2% to $2.307 million. R&D expense more than doubled as manufacturing and consulting costs increased for the new recurrent CDI trial program, while lower professional fees, legal costs, and share-based compensation reduced G&A expense.

Higher interest income partially offset the operating loss. As a result, the net loss remained close to the prior-year level even though the mix of expenses changed substantially.

Pipeline and clinical developments

The operational update remained centered on ibezapolstat, Acurx’s lead antibiotic candidate for acute and recurrent CDI. The company said a July FDA meeting produced a favorable outcome regarding its plan to conduct a single Phase 3 study and whether that study could serve as a pivotal trial for a New Drug Application. Acurx separately stated that ibezapolstat is ready to advance into international Phase 3 trials, subject to obtaining appropriate financing.

Acurx is also preparing an open-label pilot trial in patients with multiply recurrent CDI. The company attributed part of the quarter’s R&D increase to manufacturing and consulting work associated with this program.

Scientific presentations reported microbiome preservation in preclinical work and favorable ibezapolstat activity in experimental biofilm models. These findings support the program’s biological rationale but are not substitutes for successful pivotal clinical results. Subsequent developments included FDA conditional acceptance of ibezapolstat’s proprietary name, a USPTO trademark allowance, and additional patents in Japan and Mexico; none represents regulatory approval of the drug itself.

Per-share loss narrowed as equity financing expanded the share count

The reduction in loss per share did not reflect an improvement in the absolute quarterly loss. Weighted-average basic and diluted shares increased to 4.26 million from 1.19 million a year earlier, while the net loss remained near $2.25 million. The much larger denominator therefore accounted for most of the decline in loss per share.

Period-end shares outstanding also rose to 4.68 million from 2.35 million at December 31, 2025. During Q2, Acurx raised approximately $2.5 million of gross proceeds through a registered direct offering and another $0.8 million through its Equity Line of Credit. Cash consequently increased to $10.656 million from $7.556 million at year-end, an increase of approximately 41%.

The registered direct offering was accompanied by warrants to purchase up to 1.65 million shares at $2.78 per share. Exercise of those warrants or additional use of the Equity Line of Credit could further increase the share count. The release did not provide operating or free cash flow figures, so it does not allow a direct assessment of quarterly operating cash consumption.

Risks investors need to watch

• Financing and dilution: Acurx said its available funding supports the exploratory recurrent CDI trial, but advancement of the international Phase 3 program remains subject to appropriate financing. Additional equity issuance or warrant exercises could expand the share count further.
• Clinical and regulatory execution: Favorable FDA discussions and agreed trial-design elements reduce some development uncertainty, but ibezapolstat still must generate successful clinical data and obtain regulatory approval.
• Higher development spending: Q2 R&D expense rose 104% because of manufacturing and consulting costs for the recurrent CDI program. The relationship between trial progress, spending, and available cash will remain important as development advances.
• Dependence on the lead program: Ibezapolstat is the company’s principal late-stage asset, making clinical delays or unfavorable trial results particularly consequential for Acurx’s development plans.

Summary

Acurx’s Q2 2026 absolute net loss was essentially flat as higher ibezapolstat-related R&D spending offset lower administrative costs. Equity financing strengthened the cash balance, but it also materially increased the share count, which explains most of the reported improvement in per-share loss. The next important issues are financing for Phase 3 development, execution of the recurrent CDI trial, and whether ibezapolstat’s scientific findings translate into successful clinical and regulatory outcomes.